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Plasmablastic lymphoma is a rare subtype of non-Hodgkin’s lymphoma, which generally presents an aggressive 
clinical course and low survival rates. It is strongly associated with HIV infection and the most common site of 
involvement of the territory of the head and neck is Waldeyer’s lymphatic ring, followed by the gastrointestinal 
tract, lymph nodes and skin. The morphological characteristics of PBL in the oral cavity / jaw in the context of 
HIV infection show diffuse sheets of large immunoblastic cells with abundant cytoplasm, vesicular chromatin and 
prominent nucleus, a small located in the center with plasma cells differentiation. The main goal of this article is to 
review the literature of the plasmablastic lymphoma and report a case.




Plasmablastic lymphoma (PBL) is a rare subtype of 
non-Hodgkin’s lymphoma (NHL) (1), which generally 
presents an aggressive clinical course and low survival 
rates (2). The etiology of PBL is not clear, but the im-
portance of the Epstein-Barr virus (EBV) was frequently 
speculated, since it was detected in 78% of the cases (2). 
It is well known that the nature of this malignancy, that 
is, the rapid appearance of the disease, the aggressive 
invasion in extranodal sites and the frequent repetition, 
even after remission, make its prognosis extremely poor 
(1). It was described for first time in 1997, for Stein and 
coworkers, who described a series of aggressive non-Ho-
dgkin’s lymphomas (NHLs) arising in the oral cavity of 
human immunodeficiency virus (HIV)- positive patients 
(4). In 2008, the World Health Organization (WHO) ac-
cepted PBL as a special disease entity and classified it as 
an uncommon mature B-cell lymphoma, occurring most 
frequently as a mass in the oral cavity in an HIV-positive 
patient, but exceptions do exist (5).
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PBL is strongly associated with HIV infection and other 
causes of immunodeficiency, including organ transplan-
tation and advanced age. There is a percentage of male 
predominance (4:1), with approximately 70% and 80% 
of cases occurring in men, with a median age at diagno-
sis of approximately 50 years. However, patients with 
HIV infection have an earlier onset, with an average age 
at presentation of 38 years (3,6)
The most common site of involvement of the territory 
of the head and neck is Waldeyer’s lymphatic ring, fo-
llowed by the gastrointestinal tract, lymph nodes and 
skin (1,6).
In the oral cavity, the gum was the most affected site, 
followed by the palate, which usually manifests as a 
soft-tissue lesion, which is useful for differentiating PBL 
from multiple plasmacytomas / myelomas that generally 
affect the bones. The majority of PBL present as asymp-
tomatic swellings, frequency associated with ulcerations 
and hemorrhages. The most common symptoms in most 
cases, suggesting a more local involvement of the disea-
se in most cases, which is consistent with the large num-
ber of cases such as Ann Arbor stage I, or currently IE 
in the Lugano classification; although stage IV diseases 
were also frequent (2).
The morphological characteristics of PBL in the oral 
cavity / jaw in the context of HIV infection show di-
ffuse sheets of large immunoblastic cells with abundant 
cytoplasm, vesicular chromatin and prominent nucleus, 
a small located in the center. Frequent mitotic figures, 
apoptotic bodies and blended tingible body macropha-
ges (a “starry sky” appearance) are also characteristic of 
PBL, regardless of site. Confluent areas of necrosis are 
also occasionally present (3).
The characteristic immunophenotype seen in PBL in-
cludes the expression of plasmacytic differentiation 
markers including CD138, CD38, IRF4 / MUM1 (1,3), 
the little to no expression of leukocyte common antigen 
CD45 or the B – Cell Markers CD20, CD 79a, and PAX5 
(2,7,8).
The most common cytogenetic abnormality observed 
in PBL is the reorganization of the MYC gene in 8q24, 
and the immunoglobulin genes act as the most frequent 
translocation partners (3).
A treatment difference for most cases of DLBCL (Diffu-
se large B-cell lymphoma), chemotherapy with cyclo-
phosphamide, doxorubicin, vincristine, and predniso-
ne (3,9) is generally considered an inadequate therapy 
for PBL (3). Instead, more intensive parameters such 
as hyperfractionated cyclophosphamide, vincristine, 
doxorubicin, and dexamethasone alternating with me-
thotrexate and cytarabine are typically used. Because 
PBL shows a plasma differentiation criterion, agents 
that use plasma cell myeloma treatment (eg, Bortezo-
mib and lenalidomide) have also been used to treat PBL 
with some success (3). Also other authors, recommend 
radiotherapy, with or without surgical excision, or the 
combination of chemotherapy and radiotherapy (9).
Case Report
29-year-old man, heavy smoker, HIV + diagnosed 10 
years ago, at that time without antiretroviral therapy. He 
went to the Department of Medicine and Oral and Maxi-
llofacial Surgery of the Hospital El Carmen de Maipú, 
derived from periodontics due to presenting a tumora-
tion in the vestibular gingiva between teeth 1.2 and 1.3 
of 2.5 cm in diameter, of 2 weeks of evolution.
In the anamnesis, the patient referred to the minimum 
friction, without pain. No feeling of paresthesia. An 
intraoral physical examination showed an increase in 
violaceous volume, ulcerated on the surface, with a par-
tially pedicled base, asymptomatic, with the presence of 
active bleeding. Absence of other lesions in the oral ca-
vity (Fig. 1). In the orthopantomography, no osteolytic 
or radiopaque lesions were observed. No peripheral cer-
vical adenopathies were detected on palpation.
Fig. 1: Intraoral aspect of plasmablastic lymphoma.  It 
shows an increase in violaceous volume, ulcerated on 
the surface, with a partially pedicled base.
We created a list with different possible diagnosis of 
the lesion, which included: Reactive Lesion (Pyogenic 
Granuloma, peripheral giant cell granuloma, peripheral 
ossifying fibroma), Benign Neoplasm (Schwannoma), 
Kaposi Sarcoma, Angiosarcoma, lymphoma, squamous 
cell carcinoma, among others.
Laboratory tests showed a clear deficiency of CD4 cells 
(164 cells / mm3) and a high viral load (36,000 copies 
/ ml). The hemogram and coagulation test was normal, 
ESR (erythrocyte sedimentation rate) presented levels 
up to normal (27 mm/hr), which associates with the con-
dition of the patient and the lesion.
We performed an excisional biopsy with histopathologi-
cal evaluation. The histopathological examination revea-
led an oral mucosa with a lymphoplasmacytic prolifera-
tion with diffuse disposition (Fig. 2). The examination 
showed plasma cells with medium size and abundant 
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Fig. 2: Histopathological findings. It shows an oral mucosa with a 
lymphoplasmacytic proliferation with diffuse disposition.
mitosis. Immunohistochemistry showed expression of 
CD3, CD138 and KI-67 in all cells, CD30 and CD79A in 
almost all cells and CD45 in a group of cells. The sam-
ple was positive for EBV. CD20 was not expressed (Ta-
ble 1). The sample was positive to MUM-1 and EMA, 
and negative to CD56. The diagnosis was Plasmablastic 
Lymphoma, IE in the Lugano classification.
The patient was derived to San Borja Ariaran Clinical 
Hospital for treatment of plasmablastic NHL and to res-
tart therapy for HIV. The hematologist realized a ma-
rrow puncture in which they observed a bone marrow 
with PBL (around 20%)
The follow-up is described below.
• Cycles of chemotherapy EPOCH (Etoposide, predni-
sone, Viscristine Sulfate (Oncovin) and Cyclophospha-
mide) and ART (antiretroviral therapy) with Kivexa, 
Raltegravir, Norvir and Dapsone.
• 2nd Cycle Chemotherapy EPOCH with neutropenia, 
low-grade fever and pseudomembranous candidiasis.
The patient came to control with another lesion in the 
interproximal area of teeth 1.5 and 1.6 that we decided 
to observe according to the evolution of chemotherapy.
Table 1: Immunohistochemistry markers.
Four marrow punctures were performed for control:
• Two months after initiating treatment Plasmablastic 
LNH (20%)
• Four months after initiating treatment Plasmablastic 
LNH (10%)
• Six months after initiating treatment Plasmablastic 
LNH (5%)
• After 9 months initiated bone marrow treatment with 
plasmocytic infiltrate reactive aspect.
• 6 cycles of chemotherapy and remains in control by 
CD4 count at 120 cels / mm3
The patient was referred for inspection of the oral ca-
vity at the end of the chemotherapy, where no new le-
sions were observed, and with the Hematology pass the 
extraction of tooth 1.6 was programmed with a biopsy 
of the gingival lesion (Fig. 3). The biopsy of the lesion 
Fig. 3: Control after the chemotherapy. The mucosa is normal.
describe a Hyperplasia of the epitelium with fibrosis and 
inflammatory focus in the corium, without malignant 
cells.  The extraction of the  tooth 1.6 was scheduled 
because the tooth was with a Crown destruction due to 
dental caries with no possible rehab treatment.
Discussion
Patients with HIV infection have a high risk of deve-
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loping PBL. These lymphomas are characterized by a 
rapid progression, frequent extranodal initial manifes-
tation and a precarious outcome. Antiretroviral therapy 
has shown a drastic reduction in the morbidity and mor-
tality of the patient with this neoplasm. (10)
Histopathological findings in this type of lymphoma 
usually show a diffuse proliferation of predominantly 
large lymphoid cells with plasmablastic, immunoblastic 
or plasmocytic morphology. The number of more mature 
plasma cells varies from minimal to moderate in the va-
rious cases. The neoplastic cells have round nuclei, ve-
sicular chromatin, smooth nuclear contours, prominent 
central / multiple nucleoli, nuclei located eccentrically 
variable and abundant cytoplasm (11), also associa-
ted with the expression of antigens CD38, CD138 and 
MUM1 (11), but not the markers expressed by mature B 
cells, such as CD45, CD20 and PAX5 (12). Finally, EBV 
was found (2).
We made a differential diagnosis with large diffuse 
immunoblastic B cell lymphoma, ALK diffuse posi-
tive B-cell lymphoma, primary effusion lymphoma, 
anaplastic plasmacytoma (plasmablastic) and germi-
notropic lymphoproliferative disorder associated with 
Kaposi’s sarcoma-associated herpesvirus (KSHV), but 
the previous diagnosis of HIV, the laboratory findings, 
the expression of lymphoid cells with CD138, CD79a, 
weak expression of CD45, no expression of CD20 and 
presence in the oral cavity, guide for the diagnosis of 
plasmablastic lymphoma (10,13,14).
In HIV patients, a periodical oral and cervical lymph 
node examination is necessary, as it can provide impor-
tant information about the course of the disease.
The detection of malignant neoplasms should be early in 
order to provide the patient with a treatment with better 
prognosis in the short, medium and long term, as well as 
avoid possible recurrences.
The criteria of malignancy and prognosis define the 
treatment strategy with radiotherapy, associated or not 
with different chemotherapy protocols (2).
The prognosis is generally poor with a high mortality 
at a median of 6–7 months (6). The 5-year survival rate 
does not exceed 33.5%, and the presence of EBV, symp-
toms and the use of chemotherapy can help this poor 
prognosis (2).
Finally, PBL can be the first clinical manifestation of 
HIV infection, for this reason we must be vigilant to 
make an accurate and early clinical diagnosis, being able 
to differentiate a potentially malignant lesion from other 
types of oral pathology (15).
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